论文部分内容阅读
目的探讨乳腺癌组织中P-糖蛋白(P-gp)、胎盘型谷胱甘肽-S-转移酶-π(GST-π)和人表皮生长因子受体2(C-erbB-2)蛋白的表达与临床病理特征和预后的关系。方法采用免疫组化法检测48例乳腺癌组织中P-gp、GST-π和C-erbB-2蛋白表达,并对其临床病理特征和患者5年生存率进行综合分析。结果P-gp和GST-π蛋白表达与乳腺癌患者年龄、组织学分级、转移淋巴结数和TNM分期无关(P>0.05);而C-erbB-2蛋白表达与乳腺癌组织学分级、转移淋巴结数和TNM分期有关(P<0.05)。P-gp表达阳性率在C-erbB-2表达阳性的乳腺癌中显著高于C-erbB-2表达阴性的乳腺癌(P<0.05);5年内生存者的GST-π和C-erbB-2表达阳性率明显低于5年内死亡者(P<0.01)。结论P-gp参与乳腺癌的原发耐药机理,C-erbB-2表达阳性的乳腺癌发生原发性耐药的可能性较大,C-erbB-2是评估乳腺癌预后和预测治疗效果的指标。
Objective To investigate the expression of P-gp, GST-π and C-erbB-2 in breast cancer tissues The relationship between the expression and clinicopathological features and prognosis. Methods The expressions of P-gp, GST-π and C-erbB-2 in 48 cases of breast cancer were detected by immunohistochemistry, and their clinicopathological characteristics and 5-year survival rate were analyzed. Results The expression of P-gp and GST-π was not related to the age, histological grade, number of metastatic lymph nodes and TNM stage in breast cancer patients (P> 0.05). The expression of C-erbB-2 protein was correlated with histological grade, lymph node metastasis Number and TNM staging (P <0.05). The positive rate of P-gp expression in C-erbB-2 positive breast cancer was significantly higher than that in C-erbB-2 negative breast cancer (P <0.05). The positive rates of GST-π and C-erbB- 2 expression was significantly lower than those who died within 5 years (P <0.01). Conclusions P-gp is involved in the primary mechanism of breast cancer. C-erbB-2 is more likely to develop primary drug resistance in breast cancer with positive expression of C-erbB-2. C-erbB-2 is used to evaluate the prognosis and prognosis of breast cancer index of.